d-α-Tocopheryl Succinate/Phosphatidyl Ethanolamine Conjugated Amphiphilic Polymer-Based Nanomicellar System for the Efficient Delivery of Curcumin and To Overcome Multiple Drug Resistance in Cancer
Source abstract
Abstract
Nanomedicines have emerged as a promising treatment strategy for cancer. Multiple drug resistance due to overexpression of various drug efflux transporters and upregulation of apoptotic inhibitory pathways in cancer cells are major barriers that limit the success of chemotherapy. Here, we developed a d -α-tocopherol (α-TOS)/lipid-based copolymeric nanomicellar system (VPM) by conjugating phosphatidyl ethanolamine (PE) and α-TOS with poly(ethylene glycol) (PEG) via an amino acid linkage. The synthesized polymers were characterized by Fourier transform IR, gas-phase chromatography, and 1 H and 13 C NMR spectroscopy. VPM exhibited mean hydrodynamic diameter of 141.0 ± 0.94 nm with low critical micelles concentrations (CMC) of 15 μM compared to plain PEG–PE micelles (PPM) with size of 23.9 ± 0.34 nm and CMC 20 μM. The bigger hydrophobic compartment in VPM resulted in improved loading of a potent chemotherapeutic drug, curcumin (Cur), and increased encapsulation efficiency (EE) (% drug loading 98.3 ± 1.92, and 85.3 ± 3.29; EE 14.8 ± 0.16 and 12.8 ± 0.09 for VPM and PPM, respectively). Curcumin loaded Vitamin E based micelles exhibited higher cytotoxicity compared to Curcumin loaded PEG-PE micelles in tested cancer cell lines. C-VPM demonstrated ∼3.2 and ∼2.7-fold higher ability to reverse multiple drug resistance compared to PPM and verapamil (concentration used 30 μM), respectively. In the in vivo study by using B16F10 implanted C57Bl6/J mice, C-VPM reduced the tumor volume and weight more efficiently than C-PPM by inducing apoptosis as analyzed by TUNEL assay on tumor cryosections. The newly developed polymeric micelles, VPM with improved drug loadability and ability to reverse the drug resistance could successfully be utilized as a nanocarrier system for hydrophobic chemotherapeutic agents for the treatment of drug-resistant solid tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Curcumin's Biomedical Applications · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Shameerpet, Hyderabad 500078, Telangana, India
Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, Massachusetts 02115, United States
Funding
Indian Council of Medical Research · Department of Biotechnology , Ministry of Science and Technology · Department of Science and Technology, Ministry of Science and Technology
References (66)
Show source-provided references
1. 10.1016/j.biomaterials.2013.06.04610.1016/j.biomaterials.2013.06.046 ↗
2. 10.1016/j.ijpharm.2015.02.03810.1016/j.ijpharm.2015.02.038 ↗
3. 10.1016/j.addr.2013.11.00410.1016/j.addr.2013.11.004 ↗
4. 10.1007/s11095-015-1830-z10.1007/s11095-015-1830-z ↗
5. 10.1371/journal.pone.013669410.1371/journal.pone.0136694 ↗
6. 10.1016/j.vascn.2012.02.00210.1016/j.vascn.2012.02.002 ↗
7. 10.1016/j.biotechadv.2013.11.00910.1016/j.biotechadv.2013.11.009 ↗
8. 10.1016/j.jconrel.2012.01.00910.1016/j.jconrel.2012.01.009 ↗
9. 10.1016/j.nano.2013.07.01610.1016/j.nano.2013.07.016 ↗
10. 10.3109/1061186X.2010.53698310.3109/1061186X.2010.536983 ↗
11. 10.1016/j.actbio.2013.12.03310.1016/j.actbio.2013.12.033 ↗
12. 10.1021/mp300729y10.1021/mp300729y ↗
13. 10.1016/j.ijpharm.2014.01.00910.1016/j.ijpharm.2014.01.009 ↗
14. 10.1016/j.biomaterials.2012.08.07210.1016/j.biomaterials.2012.08.072 ↗
15. 10.1016/j.ejps.2012.02.01010.1016/j.ejps.2012.02.010 ↗
16. 10.1016/j.biomaterials.2011.04.03710.1016/j.biomaterials.2011.04.037 ↗
17. 10.1016/j.ejpb.2015.07.02210.1016/j.ejpb.2015.07.022 ↗
18. 10.3109/03639045.2014.93539010.3109/03639045.2014.935390 ↗
19. 10.1016/j.colsurfb.2015.06.01810.1016/j.colsurfb.2015.06.018 ↗
20. 10.1016/j.bmc.2013.12.03610.1016/j.bmc.2013.12.036 ↗
21. 10.1042/bj362070910.1042/bj3620709 ↗
22. Kline K. · J. Nutr. · 2001 · 131 · 161S10.1093/jn/131.1.161S ↗
23. Yu W. · Cancer Res. · 2001 · 61 · 6569
24. 10.1207/S15327914NC432_1310.1207/S15327914NC432_13 ↗
25. 10.1002/pros.2046810.1002/pros.20468 ↗
26. 10.1016/j.jconrel.2014.03.00910.1016/j.jconrel.2014.03.009 ↗
27. 10.1016/j.ejps.2013.02.00610.1016/j.ejps.2013.02.006 ↗
28. 10.1211/jpp.59.4.000110.1211/jpp.59.4.0001 ↗
29. 10.1016/j.foodres.2014.12.04510.1016/j.foodres.2014.12.045 ↗
30. 10.1002/(SICI)1097-4644(1997)27+<26::AID-JCB7>3.3.CO;2-Q10.1002/(SICI)1097-4644(1997)27+<26::AID-JCB7>3.3.CO;2-Q ↗
31. 10.1038/mt.2015.16510.1038/mt.2015.165 ↗
32. 10.3109/10717544.2013.87350110.3109/10717544.2013.873501 ↗
33. Danafar H. · Adv. Pharm. Bull. · 2014 · 4 · 501
34. 10.1038/gt.2014.9710.1038/gt.2014.97 ↗
35. 10.2217/nnm.11.9310.2217/nnm.11.93 ↗
36. 10.1016/j.ijpharm.2014.05.05910.1016/j.ijpharm.2014.05.059 ↗
37. 10.1016/j.ejpb.2011.04.01710.1016/j.ejpb.2011.04.017 ↗
38. 10.1016/j.colsurfb.2014.05.00510.1016/j.colsurfb.2014.05.005 ↗
39. 10.1016/j.ijbiomac.2010.11.00510.1016/j.ijbiomac.2010.11.005 ↗
40. 10.1016/j.actbio.2013.06.04110.1016/j.actbio.2013.06.041 ↗
41. 10.1016/j.nano.2011.06.01110.1016/j.nano.2011.06.011 ↗
42. 10.1016/j.ijpharm.2006.02.01810.1016/j.ijpharm.2006.02.018 ↗
43. 10.1158/1535-7163.MCT-06-008710.1158/1535-7163.MCT-06-0087 ↗
44. 10.1016/j.ijpharm.2010.10.04110.1016/j.ijpharm.2010.10.041 ↗
45. 10.1016/j.biomaterials.2011.09.07710.1016/j.biomaterials.2011.09.077 ↗
46. 10.1016/j.bbagen.2014.06.00410.1016/j.bbagen.2014.06.004 ↗
47. 10.1016/j.biomaterials.2014.02.02210.1016/j.biomaterials.2014.02.022 ↗
48. 10.1016/j.biomaterials.2011.02.02210.1016/j.biomaterials.2011.02.022 ↗
49. 10.1016/j.jconrel.2012.05.03110.1016/j.jconrel.2012.05.031 ↗
50. 10.1021/j100449a01210.1021/j100449a012 ↗
51. 10.1080/1061186X.2016.125856710.1080/1061186X.2016.1258567 ↗
52. 10.1016/j.bbamem.2008.01.00610.1016/j.bbamem.2008.01.006 ↗
53. 10.1016/j.bbamem.2012.06.01910.1016/j.bbamem.2012.06.019 ↗
54. 10.1021/bc010048h10.1021/bc010048h ↗
55. 10.1016/j.colsurfb.2004.04.00610.1016/j.colsurfb.2004.04.006 ↗
56. 10.1016/j.colsurfa.2011.10.01210.1016/j.colsurfa.2011.10.012 ↗
57. 10.1016/0009-8981(88)90110-610.1016/0009-8981(88)90110-6 ↗
58. 10.1021/mp800158c10.1021/mp800158c ↗
59. 10.1016/j.biomaterials.2011.12.04210.1016/j.biomaterials.2011.12.042 ↗
60. 10.1016/j.ijpharm.2015.10.00910.1016/j.ijpharm.2015.10.009 ↗
61. 10.1042/bj362070910.1042/bj3620709 ↗
62. 10.1016/j.drudis.2013.09.00910.1016/j.drudis.2013.09.009 ↗
63. 10.1016/j.biomaterials.2013.12.09010.1016/j.biomaterials.2013.12.090 ↗
64. 10.1208/s12248-015-9811-z10.1208/s12248-015-9811-z ↗
65. 10.1016/j.biomaterials.2013.12.09610.1016/j.biomaterials.2013.12.096 ↗
66. 10.1016/j.ijpharm.2011.09.00810.1016/j.ijpharm.2011.09.008 ↗